DEA Regulations for Telehealth Ketamine: Schedule III Rules, Ryan Haight, and Exemptions

DEA regulations for telehealth ketamine currently allow prescribers to issue Schedule III ketamine prescriptions after a video evaluation, without the in-person exam federal law once required. That flexibility comes from temporary orders the Drug Enforcement Administration has issued and repeatedly extended since the COVID-19 public health emergency, not from a permanent rule change. The DEA's proposed permanent framework, a special registration for telemedicine prescribing, has been in development since 2018 and is still unfinished. This matters for patients and providers alike, because the rules that currently make direct-to-consumer telehealth ketamine possible could tighten once the DEA finalizes permanent regulations. Below is a breakdown of ketamine's Schedule III classification, the Ryan Haight Act that originally barred this model, the COVID-era exemptions that opened it, and what compliance looks like for providers today.

Ketamine is a Schedule III controlled substance under the Controlled Substances Act, the federal law that ranks drugs by medical use and potential for abuse. According to the DEA's Diversion Control Division, Schedule III substances have an accepted medical use, moderate to low potential for physical dependence, and moderate potential for psychological dependence (DEA Diversion Control Division). That places ketamine under looser restrictions than Schedule I or II drugs, but it is still subject to specific prescribing and dispensing rules.

Ketamine prescriptions can be written, phoned to a pharmacy, or submitted electronically. Electronic prescribing of controlled substances (EPCS) is now standard for Schedule III drugs. A Schedule III prescription can be refilled up to five times within six months of the original issue date. After that window or refill count, the prescriber must issue a new prescription.

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 is the law that originally blocked most telehealth ketamine prescribing. Congress passed it after a California teenager died from a controlled substance he obtained through an online pharmacy without a legitimate prescription. The Act required an in-person medical evaluation before a practitioner could prescribe a controlled substance, with narrow exceptions for patients at a DEA-registered hospital or clinic. It had no exception for a patient at home connecting to a provider by video, the model most telehealth ketamine clinics use today. That gap effectively barred direct-to-consumer telehealth ketamine prescribing until 2020.

On March 16, 2020, the DEA issued a temporary order letting DEA-registered practitioners prescribe controlled substances, including Schedule III ketamine, by telemedicine without a prior in-person evaluation. The order required a legitimate medical purpose, an established patient-practitioner relationship (which the telemedicine visit itself could establish), and compliance with applicable state law. That order created the legal basis for the telehealth ketamine industry's growth after 2020. For how these federal flexibilities line up with individual state licensing and prescribing rules, see our telehealth law roundup.

The SUPPORT for Patients and Communities Act of 2018 directed the DEA to create a special registration allowing certain practitioners to prescribe controlled substances by telemedicine without a prior in-person visit. In 2023, the DEA proposed two categories. Category 1 would let registered practitioners prescribe non-narcotic Schedule III-V drugs, including ketamine, by telemedicine, but limited each prescription to a 30-day supply, required a state prescription drug monitoring program (PDMP) check and government-issued ID, and required an in-person evaluation before a second prescription. Category 2 would let practitioners with a special telemedicine registration prescribe Schedule II-V drugs indefinitely under ongoing PDMP and identity-verification requirements. According to the DEA's public comment docket, the 2023 proposal drew more than 38,000 comments, many from telehealth providers who argued the 30-day limit and in-person requirement for a second prescription were operationally unworkable. The DEA withdrew the proposed rules for revision, and finalized permanent rules remain pending.

DEA regulations require practitioners to keep records of controlled substance prescriptions for at least two years. For telehealth ketamine, that record should document the telemedicine encounter, the clinical rationale for prescribing, and any PDMP check performed. A prescription drug monitoring program is a state-run database that tracks controlled substance prescriptions to help identify potential misuse. Most states require a PDMP check before a controlled substance prescription is issued, but specifics vary. Some states require a check for every Schedule II-V prescription, some limit it to Schedule II-III, and some set a checking frequency, such as every 90 days. A provider licensed across multiple states has to track each state's requirement individually. Our state regulations overview covers how these state-level rules interact with the federal framework described here.